Darshana Patil

Dr. Darshana Patil


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TCTim R. Crook
Tim R. Crook
RLRobert Charles Leonard
Robert Charles Leonard
Kefah MokbelKefah Mokbel
Kefah Mokbel
ATAlastair Thompson
Alastair Thompson
MMMichael Michell
Michael Michell
RDRajan Bhalchandra Datar
Rajan Bhalchandra Datar
Background: The early detection of breast cancer (BrC) is associated with improved survival. We describe a blood-based breast cancer detection test based on functional enrichment of breast-adenocarcinoma-associated circulating tumor cells (BrAD-CTCs) and their identification via multiplexed fluorescence immunocytochemistry (ICC) profiling for GCDFP15, GATA3, EpCAM, PanCK, and CD45 status. Methods: The ability of the test to differentiate BrC cases (N = 548) from healthy women (N = 9632) was evaluated in a case–control clinical study. The ability of the test to differentiate BrC cases from those with benign breast conditions was evaluated in a prospective clinical study of women (N = 141) suspected of BrC. Results: The test accurately detects BrAD-CTCs in breast cancers, irrespective of age, ethnicity, disease stage, grade, or hormone receptor status. Analytical validation established the high accuracy and reliability of the test under intended use conditions. The test detects and differentiates BrC cases from healthy women with 100% specificity and 92.07% overall sensitivity in a case–control study. In a prospective clinical study, the test shows 93.1% specificity and 94.64% overall sensitivity in differentiating breast cancer cases (N = 112) from benign breast conditions (N = 29). Conclusion: The findings reported in this manuscript support the clinical potential of this test for blood-based BrC detection.

Verified
Journal Article
Open access
PDF file
ARAnup Ranade
Anup Ranade
DPDarshana Patil
Darshana Patil
ABAmit Bhatt
Amit Bhatt
RDRucha Dhasare
Rucha Dhasare
Vineet DattaVineet Datta
Vineet Datta
DADadasaheb Akolkar
Dadasaheb Akolkar
In this paper we report long-term therapy management based on iterative de novo molecular and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior history of treated colorectal cancer. In the described case temporal tumor evolution, emergent therapy resistance and disease recurrences were addressed via the administration of personalized label- and organ-agnostic treatments based on de novo tumor profiling. This adaptive and iterative treatment strategy countered disease progression at each instance and led to the durable regression of primary as well as metastatic lesions. Concurrently, serial evaluation of mutations in cell-free circulating tumor DNA (ctDNA) via liquid biopsy (LBx) was performed to monitor disease status, ascertain treatment response, identify emergent drug resistance and detect recurrence at sub-radiological levels. The treatment management strategy described herein effectively addressed multiple, sequential clinical conundrums for which viable options were unavailable under the current Standard of Care (SoC).

27 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DADadasaheb Akolkar
Dadasaheb Akolkar
SPSneha Shripad Puranik
Sneha Shripad Puranik
AAApurwa Apurwa
Apurwa Apurwa
SCShivani Vijay Chaudhari
Shivani Vijay Chaudhari
PNPratiksha Sunil Nandre
Pratiksha Sunil Nandre
RDRajan Bhalchandra Datar
Rajan Bhalchandra Datar
Background: Radiological assessment of treatment response in advanced solid tumors is episodic and may delay recognition of biological progression. We evaluated personalized tumor-informed circulating tumor DNA (ctDNA) monitoring using droplet digital PCR (ddPCR) to determine its association with radiological response and tumor burden, characterize longitudinal molecular–radiological concordance, quantify molecular lead time (MLT), and assess real-world implementation. Methods: Serial plasma ctDNA monitoring was performed in 61 patients between 2017-2019 with advanced solid tumors using personalized ddPCR assays targeting patient-specific somatic driver variants. ctDNA variant allele fraction (VAF) was compared across Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) categories and evaluated in relation to estimated tumor volume and RECIST sum of longest diameters (SLD). Longitudinal trajectories were assessed using predefined Longitudinal Concordance Level (LCL), molecular progression, and Molecular Evidence Level (MEL) frameworks. A follow-up independent real-world cohort of 270 patients tested between 2021 and 2026 was analyzed to assess operational feasibility and scalability under routine clinical laboratory conditions. Results: A total of 385 longitudinal ctDNA assessments were performed, of which 357 were imaging-concurrent and comprised 90 partial response (PR), 117 stable disease (SD), and 150 progressive disease (PD) observations. ctDNA VAF differed significantly across RECIST categories (Kruskal–Wallis H = 19.09, p = 0.000072), with median VAF increasing from 0.055% in PR to 0.190% in SD and 0.210% in PD. In the primary tumor-burden analysis of 210 imaging–ctDNA pairs from 53 patients, ctDNA VAF showed weak positive correlations with estimated tumor volume (Spearman ρ = 0.169, p = 0.0144) and RECIST SLD (ρ = 0.177, p = 0.0101); both associations remained significant in mixed-effects models accounting for repeated measurements. Across 50 evaluable longitudinal trajectories, 21 (42.0%) demonstrated strong molecular–radiological concordance. Among 14 patients who developed radiological progression after an initial PR or SD, molecular progression preceded radiological progression in 9 (64.3%), with a median MLT of 55 days (IQR 46–83; range 28–209; Wilcoxon signed-rank p = 0.0039). In the real-world cohort, 650 personalized ddPCR assays were performed across five genomic alteration classes - 494 single-nucleotide variant, 93 insertion/deletion, 53 copy-number amplification, 7 fusion, and 3 promoter mutation assays - with a median assay-specific limit of detection of 0.020% VAF (IQR 0.020–0.030%). Conclusions: Personalized tumor-informed ddPCR complements radiological assessment by distinguishing response states at the population level, characterizing longitudinal molecular–radiological concordance, and identifying molecular progression before conventional imaging in selected patients. The substantial overlap in absolute VAF across response categories and the weak association with anatomical tumor burden support interpretation of serial within-patient molecular trajectories rather than universal VAF thresholds. Real-world implementation across 270 patients and five genomic alteration classes further supports the operational feasibility and scalability of this approach and provides a framework for prospective ctDNA-guided interventional studies.

Verified
Journal Article
Open access
PDF file
DADadasaheb Akolkar
Dadasaheb Akolkar
SPSneha Shripad Puranik
Sneha Shripad Puranik
AAApurwa Apurwa
Apurwa Apurwa
SCShivani Vijay Chaudhari
Shivani Vijay Chaudhari
PNPratiksha Sunil Nandre
Pratiksha Sunil Nandre
RDRajan Bhalchandra Datar
Rajan Bhalchandra Datar
Serial circulating tumor DNA (ctDNA) monitoring may complement episodic radiological response assessment during systemic therapy. We evaluated personalized tumor-informed droplet digital PCR (ddPCR) for longitudinal ctDNA monitoring in advanced solid tumors, focusing on RECIST-associated ctDNA levels, anatomical tumor burden, molecular–radiological concordance, molecular lead time (MLT), and routine implementation. The clinical cohort comprised 61 patients with breast, colorectal, gynecological, head and neck, lung, pancreaticobiliary, or other advanced solid tumors and 385 longitudinal patient-specific ddPCR assessments; 357 assessments were imaging-concurrent. Repeated RECIST-stratified measurements were evaluated descriptively and using patient-clustered generalized estimating equations (GEEs). Longitudinal trajectories were classified using study-specific Longitudinal Concordance Level (LCL) and Molecular Evidence Level (MEL) frameworks. A separate real-world implementation cohort comprised 270 patients and 650 personalized ddPCR assays; 88 patients underwent two or more serial assessments. Among the 357 imaging-concurrent assessments, 90 were partial response (PR), 117 stable disease (SD), and 150 progressive disease (PD). Median VAF was 0.055% in PR, 0.190% in SD, and 0.205% in PD. Patient-clustered GEEs confirmed an overall association between VAF and RECIST category (Wald χ2 = 12.60, p = 0.00183), with lower VAF in PR than SD (Holm-adjusted p = 0.00119) or PD (p = 0.00247), but no separation between SD and PD (p = 0.539). In 210 imaging–ctDNA pairs from 53 patients, correlations with estimated tumor volume (ρ = 0.169) and RECIST SLD (ρ = 0.177) were weak. Of 50 evaluable longitudinal trajectories, 21 (42.0%) were LCL-1. Among 14 patients who developed radiological PD after an initial PR or SD, molecular progression preceded radiological progression in 9 (64.3%), was concurrent in 3 (21.4%), and no qualifying pre-radiological molecular-progression event was identified in 2 (14.3%); positive MLTs had a median of 55 days (IQR 46–83; range 28–209). The real-world cohort included five genomic alteration classes and a median assay-specific LoD of 0.020% VAF (IQR 0.020–0.030%). Personalized tumor-informed ddPCR showed population-level association with RECIST response and structured longitudinal molecular–radiological relationships, while substantial VAF overlap and weak anatomical-burden correlations limit interpretation of isolated measurements. Molecular progression preceded imaging-defined progression in a subset of patients, supporting prospective evaluation of ctDNA-triggered reassessment rather than establishing benefit from ctDNA-guided intervention. The separate real-world cohort supports operational feasibility across diverse assay designs.

20 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MCMassimo Cristofanilli
Massimo Cristofanilli
SLSewanti Limaye
Sewanti Limaye
NRNitesh Rohatgi
Nitesh Rohatgi
TCTim R. Crook
Tim R. Crook
HAHumaid O Al-Shamsi
Humaid O Al-Shamsi
RDRajan Bhalchandra Datar
Rajan Bhalchandra Datar
Background/Objectives: Circulating tumor-associated cells (CTACs) are rare among peripheral blood nucleated cells (PBNCs), creating a challenge for image-based multi-cancer detection. We evaluated a predefined CTAC-detection pipeline incorporating Attention U-Net segmentation, post-processing, cytological feature extraction, and Random Forest classification. Methods: Model suitability was explored in asymptomatic individuals and patients with advanced solid tumors. Clinical performance was assessed in a case–control cohort of therapy-naive stage I/II cancers, benign conditions, and asymptomatic individuals, followed by four prospective cohort evaluations performed within the same laboratory and imaging workflow: recurrent cancer with low radiological tumor burden, peri-operative solid tumors, suspected cancer, and asymptomatic screening. PBNCs were stained with EpCAM/Hoechst 33342 and imaged. Pathologists’ review established ground truth annotations. Results: The model had 90.68% sensitivity and 99.53% specificity in the exploratory study. In the case–control cohort, sensitivity was 88.65% in therapy-naive stage I/II cancers, while specificity was 78.95% in benign conditions and >99.9% in asymptomatic individuals. In the prospective cohorts, CTAC detection sensitivity was 91.96% in pretreated low tumor burden cases; CTACs were detected in 100% of pre-surgery specimens and 29.41% of post-surgery specimens; and in suspected cancer cases, the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were 96.34% and 32.35%, respectively. In the asymptomatic screening cohort, 44/7183 participants were CTAC-positive; 16 had confirmed Stage I/II cancer, 10 had no radiologically detectable disease at the available assessment, and 18 remained unresolved. The conservative lower-bound PPV was 36.36%, and the NPV was 99.97%; estimates remain provisional pending complete follow-up. Conclusions: The integrated Attention U-Net/feature-based classification pipeline demonstrated consistent CTAC detection across the evaluated cohorts and supports its potential clinical utility for cancer detection.